Vodafone shares surge 7% after earnings report; European stock markets close higher

European markets closed higher, driven by earnings reports from companies like Swiss Life and Greggs, while Vodafone shares surged despite posting a €411 million loss for 2025 due to impairment charges, though revenue increased 2%. Novo Nordisk saw a 3% increase as traders digested the CEO shake-up amidst competition in the weight loss drug market. UBS shares dipped following a report suggesting the Swiss government may require the bank to hold an additional $25 billion in loss-absorption capital.

Analysis

European stock markets, including the Stoxx Europe 600, FTSE 100, CAC, and DAX, closed higher, buoyed by a series of corporate earnings reports. Vodafone (VOD) shares surged 7.2% despite reporting a full-year operating loss of €411 million for 2025, a stark contrast to the previous year's €3.7 billion profit, primarily due to €4.5 billion in impairment charges for Germany and Romania. However, Vodafone's total revenue rose 2% to €37.4 billion, and its 2025 adjusted EBITDAaL of €11 billion met guidance, with JPMorgan noting that while German operations underperformed, the overall group forecasts are expected to remain broadly unchanged. The company cautioned that "significant uncertainties" in the macroeconomic climate, particularly trade and foreign exchange, could impact its 2026 performance, for which it projects adjusted EBITDAaL between €11 billion and €13 billion. Greggs (GRG.L) shares rose 9% after announcing a 7.4% year-on-year sales jump to £784 million for the 20 weeks to May 17, driven by "product innovation" and plans to open 140-150 net new stores in the full year; like-for-like sales in company-managed stores increased 2.9%. Investec issued a "buy" rating for Greggs, citing its growth opportunity and improving cash generation. Swiss Life reported a 3% year-on-year rise in first-quarter fee income to 659 million Swiss francs and a 6% increase in premiums to 7.9 billion Swiss francs. Novo Nordisk (NVO) shares increased 3.3% as markets processed the news of CEO Lars Fruergaard Jørgensen's impending departure amid intense competition in the obesity drug market from Eli Lilly's Zepbound and challenges from compounded versions of Wegovy; analysts noted the CEO's departure as a "gigantic surprise" but also highlighted the more than tripling of share price during his tenure. Conversely, UBS (UBS) shares dipped 2.57% following a report that the Swiss government might impose additional capital requirements of up to $25 billion, a move stemming from concerns about the bank's size relative to the Swiss economy after its absorption of Credit Suisse. Swedish tech group Lagercrantz reported a 16% annual increase in profit to 1.02 billion SEK and a 16% revenue growth to 9.39 billion SEK, attributed to its "build-and-buy" acquisition strategy, and expressed optimism despite geopolitical uncertainties. ECB Executive Board member Isabel Schnabel highlighted a "historical opportunity" for the euro, which has gained 9% against the U.S. dollar year-to-date.

Key Decisions for Investors

• Investors should closely monitor Vodafone's German operational improvements and the materialization of macroeconomic uncertainties which could affect its 2026 guidance, despite the market's positive reaction to its recent earnings.
• Greggs' strong sales momentum, driven by product innovation and aggressive store expansion plans, alongside a favorable analyst valuation, suggests potential for continued growth, warranting attention to the execution of its expansion strategy and sustained like-for-like sales.
• The leadership transition at Novo Nordisk amidst significant competitive pressures in the lucrative obesity drug market necessitates careful observation of the new CEO's strategy to navigate challenges from rivals like Eli Lilly and compounded drug versions.
• The potential for substantial additional capital requirements at UBS presents a significant overhang; investors should await clarity on the Swiss government's final decision in early June and evaluate its impact on the bank's capital efficiency and competitive positioning.
• Lagercrantz's consistent execution of its 'build-and-buy' strategy yielding robust profit growth is a positive indicator, though vigilance regarding the impact of trade uncertainties on its M&A-driven model is prudent.